Standardized definitions for hemodialysis vascular access

Timmy Lee, Michele Mokrzycki, Louise Moist, Ivan Maya, Miguel Vazquez, Charmaine E Lok, North American Vascular Access Consortium, Timmy Lee, Michele Mokrzycki, Louise Moist, Ivan Maya, Miguel Vazquez, Charmaine E Lok, North American Vascular Access Consortium

Abstract

Vascular access dysfunction is one of the leading causes of morbidity and mortality among end-stage renal disease patients. Vascular access dysfunction exists in all three types of available accesses: arteriovenous fistulas, arteriovenous grafts, and tunneled catheters. To improve clinical research and outcomes in hemodialysis (HD) access dysfunction, the development of a multidisciplinary network of collaborative investigators with various areas of expertise, and common standards for terminology and classification in all vascular access types, is required. The North American Vascular Access Consortium (NAVAC) is a newly formed multidisciplinary and multicenter network of experts in the area of HD vascular access, who include nephrologists and interventional nephrologists from the United States and Canada with: (1) a primary clinical and research focus in HD vascular access dysfunction, (2) national and internationally recognized experts in vascular access, and (3) a history of productivity measured by peer-reviewed publications and funding among members of this consortium. The consortium's mission is to improve the quality and efficiency in vascular access research, and impact the research in the area of HD vascular access by conducting observational studies and randomized controlled trials. The purpose of the consortium's initial manuscript is to provide working and standard vascular access definitions relating to (1) epidemiology, (2) vascular access function, (3) vascular access patency, and (4) complications in vascular accesses relating to each of the vascular access types.

© 2011 Wiley Periodicals, Inc.

References

    1. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA. Hemodialysis vascular access morbidity in the United States. Kidney Int. 1993;43:1091–1096.
    1. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–535.
    1. Murad MH, Swiglo BA, Sidawy AN, Ascher E, Montori VM. Methodology for clinical practice guidelines for the management of arteriovenous access. J Vasc Surg. 2008;48:26S–30S.
    1. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg. 2002;35:603–610.
    1. Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. J Vasc Interv Radiol. 2003;14:S433–S442.
    1. Spergel LM, Ravani P, Asif A, Roy-Chaudhury P, Besarab A. Autogenous arteriovenous fistula options. J Nephrol. 2007;20:288–298.
    1. Dember LM, Kaufman JS, Beck GJ, et al. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials. 2005;2:413–422.
    1. Dixon BS, Beck GJ, Dember LM, et al. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clin Trials. 2005;2:400–412.
    1. Huijbregts HJT, Bots ML, Wittens CHA, et al. Hemodialysis Arteriovenous Fistula Patency Revisited: Results of a Prospective, Multicenter Initiative. Clin J Am Soc Nephrol. 2008 CJN.02950707.
    1. Aad G, Abbott B, Abdallah J, et al. Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Physical review letters. 2010;105:252303.
    1. Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis. 2006;48:S176–S273.
    1. Paulson WD, Moist L, Lok CE. Vascular Access Surveillance: An Ongoing Controversy. Kidney Int. 2011 (in press)
    1. Dember LM, Beck GJ, Allon M, et al. Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis: A Randomized Controlled Trial. JAMA. 2008;299:2164–2171.
    1. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of early fistula failure. Kidney Int. 2003;64:1487–1494.
    1. Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I) J Am Soc Nephrol. 2006;17:3204–3212.
    1. Huber TS, Ozaki CK, Flynn TC, et al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J Vasc Surg. 2002;36:452–459.
    1. Lee T, Barker J, Allon M. Needle infiltration of arteriovenous fistulae in hemodialysis: risk factors and consequences. Am J Kidney Dis. 2006;47:1020–1026.
    1. Asif A, Cherla G, Merrill D, et al. Venous mapping using venography and the risk of radiocontrast-induced nephropathy. Semin Dial. 2005;18:239–242.
    1. Kian K, Wyatt C, Schon D, Packer J, Vassalotti J, Mishler R. Safety of low-dose radiocontrast for interventional AV fistula salvage in stage 4 chronic kidney disease patients. Kidney Int. 2006;69:1444–1449.
    1. Allan JC, Bertram K, Charles H, et al. United States Renal Data System 2006 Annual Data Report Abstract. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006;49:A6–A7.
    1. Lafrance JP, Rahme E, Lelorier J, Iqbal S. Vascular access-related infections: definitions, incidence rates, and risk factors. Am J Kidney Dis. 2008;52:982–993.
    1. Lok CE, Oliver MJ. Overcoming barriers to arteriovenous fistula creation and use. Semin Dial. 2003;16:189–196.
    1. Mokrzycki MH, Lok CE. Traditional and non-traditional strategies to optimize catheter function: go with more flow. Kidney Int. 2010;78:1218–1231.
    1. Asif A, Merrill D, Briones P, Roth D, Beathard GA. Hemodialysis vascular access: percutaneous interventions by nephrologists. Semin Dial. 2004;17:528–534.
    1. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis. 2004;44:779–791.
    1. Lok CE, Mokrzycki MH. Prevention and management of catheter-related infection in hemodialysis patients. Kidney Int. 2011;79:587–598.
    1. Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant. 2004;19:670–677.
    1. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol. 2002;13:2133–2139.
    1. Schwab SJ, Weiss MA, Rushton F, et al. Multicenter clinical trial results with the LifeSite hemodialysis access system. Kidney Int. 2002;62:1026–1033.
    1. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol. 2003;14:169–179.
    1. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009;49:1–45.
    1. Preventing infections associated with indwelling intravascular access devices. Can Commun Dis Rep. 1997;23(Suppl 8):i–iii. 1–32, i–iv, 1–16.
    1. Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med. 2011;364:303–312.
    1. National Kidney Foundation: DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. Am J Kidney Dis. 2001;37:S137–S81.
    1. Moist LM, Hemmelgarn BR, Lok CE. Relationship between blood flow in central venous catheters and hemodialysis adequacy. Clinical journal of the American Society of Nephrology : CJASN. 2006;1:965–971.
    1. Beathard GA. Catheter thrombosis. Seminars in dialysis. 2001;14:441–445.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa